Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2023)
Denali Therapeutics (DNLI) reported Other Non-Current Liabilities of $379000.0 for Q3 2023, little changed year-over-year from $379000.0 in Q3 2022, and little changed on a QoQ basis from $379000.0 in Q2 2023.
Denali Therapeutics (DNLI) has 7 years of Other Non-Current Liabilities data on file, last reported at $379000.0 in Q3 2023.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $379000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $379000.0 (changed 0.0% YoY) and the FY2022 annual result came in at $379000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities held at $379000.0 in Q3 2023 per DNLI's latest filing, from $379000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $701000.0 in Q4 2020 and bottomed at $379000.0 in Q4 2019.
- The 5-year median for Other Non-Current Liabilities is $379000.0 (2019), against an average of $451894.7.
- The widest annual swing landed in 2019, when Other Non-Current Liabilities surged 211.29%; it then slumped 45.93% in 2021.
- Tracing DNLI's Other Non-Current Liabilities over 5 years: stood at $379000.0 in 2019, then surged by 84.96% to $701000.0 in 2020, then tumbled by 45.93% to $379000.0 in 2021, then changed by 0.0% to $379000.0 in 2022, then changed by 0.0% to $379000.0 in 2023.
- Per Business Quant, the three latest DNLI Other Non-Current Liabilities figures stand at $379000.0 (Q3 2023), $379000.0 (Q2 2023), and $379000.0 (Q1 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 379,000.00 |
| Jun 30, 2023 | 379,000.00 |
| Mar 31, 2023 | 379,000.00 |
| Dec 31, 2022 | 379,000.00 |
| Sep 30, 2022 | 379,000.00 |
| Jun 30, 2022 | 379,000.00 |
| Mar 31, 2022 | 379,000.00 |
| Dec 31, 2021 | 379,000.00 |
| Sep 30, 2021 | 701,000.00 |
| Jun 30, 2021 | 701,000.00 |
| Mar 31, 2021 | 701,000.00 |
| Dec 31, 2020 | 701,000.00 |
| Sep 30, 2020 | 379,000.00 |
| Jun 30, 2020 | 379,000.00 |
| Mar 31, 2020 | 379,000.00 |
| Dec 31, 2019 | 379,000.00 |
| Sep 30, 2019 | 386,000.00 |
| Jun 30, 2019 | 408,000.00 |
| Mar 31, 2019 | 440,000.00 |
| Dec 31, 2018 | 471,000.00 |
| Sep 30, 2018 | 124,000.00 |
| Jun 30, 2018 | 156,000.00 |
| Mar 31, 2018 | 188,000.00 |
| Dec 31, 2017 | 467,000.00 |